Sumitomo Pharma's Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive ...

Imbrium Therapeutics L.P. ("Imbrium"), a subsidiary of Purdue Pharma L.P. ("Purdue"), announced results from a Phase 1b clinical signal detection study evaluating the safety and efficacy of the novel ...

An overactive bladder may be temporary or become a chronic condition. How long the symptoms last may depend on factors like the underlying cause and treatment adherence. Some conditions may cause ...

The FDA has approved Gemtesa® for men with overactive bladder symptoms receiving pharmacological therapy for BPH.

Gemtesa is approved for men with overactive bladder symptoms who are receiving pharmacologic treatment for benign prostatic hyperplasia.

Anticholinergics are competitive inhibitors of acetylcholine at muscarinic receptors (mainly the M3 receptor subtype), and they thereby inhibit involuntary bladder contractions. [19] The effective ...

It's a CR Best Buy because it has a lower risk of side effects. You might not even have an overactive bladder. Symptoms that are associated with diabetes, kidney stones, multiple sclerosis ...